Last reviewed · How we verify
RSV Polyclonal Immunoglobulin
RSV Polyclonal Immunoglobulin is a Polyclonal immunoglobulin Small molecule drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently FDA-approved for Prevention of serious lower respiratory tract RSV infection in high-risk infants and young children (including premature infants and those with congenital heart disease or chronic lung disease).
RSV polyclonal immunoglobulin provides passive immunity by supplying antibodies that bind to respiratory syncytial virus and neutralize its infectivity.
RSV Polyclonal Immunoglobulin is used to prevent Respiratory Syncytial Virus Infections in specific populations, such as bone marrow transplant recipients. It is a replacement therapy with immunomodulatory effects, although its exact modality is unknown.
At a glance
| Generic name | RSV Polyclonal Immunoglobulin |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Polyclonal immunoglobulin |
| Target | Respiratory syncytial virus (RSV) surface proteins |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This product is a polyclonal antibody preparation derived from human plasma of donors with high titers of RSV-specific antibodies. When administered intravenously, these antibodies directly bind to RSV surface proteins, preventing viral attachment and entry into host cells, thereby reducing viral replication and disease severity. This passive immunization approach provides immediate but temporary protection, particularly in high-risk populations.
Approved indications
- Prevention of serious lower respiratory tract RSV infection in high-risk infants and young children (including premature infants and those with congenital heart disease or chronic lung disease)
Common side effects
- Fever
- Injection site reactions
- Hypersensitivity reactions
- Myalgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RSV Polyclonal Immunoglobulin CI brief — competitive landscape report
- RSV Polyclonal Immunoglobulin updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about RSV Polyclonal Immunoglobulin
What is RSV Polyclonal Immunoglobulin?
How does RSV Polyclonal Immunoglobulin work?
What is RSV Polyclonal Immunoglobulin used for?
Who makes RSV Polyclonal Immunoglobulin?
What drug class is RSV Polyclonal Immunoglobulin in?
What development phase is RSV Polyclonal Immunoglobulin in?
What are the side effects of RSV Polyclonal Immunoglobulin?
What does RSV Polyclonal Immunoglobulin target?
Related
- Drug class: All Polyclonal immunoglobulin drugs
- Target: All drugs targeting Respiratory syncytial virus (RSV) surface proteins
- Manufacturer: National Institute of Allergy and Infectious Diseases (NIAID) — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of serious lower respiratory tract RSV infection in high-risk infants and young children (including premature infants and those with congenital heart disease or chronic lung disease)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing